(Q43738820)

26 November 2017

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies (English)

1 reference

26 November 2017

0 references

H E Bays

1

1 reference

26 November 2017

P B Moore

2

1 reference

26 November 2017

M A Drehobl

3

1 reference

26 November 2017

S Rosenblatt

4

1 reference

26 November 2017

P D Toth

5

1 reference

26 November 2017

C A Dujovne

6

1 reference

26 November 2017

R H Knopp

7

1 reference

26 November 2017

L J Lipka

8

1 reference

26 November 2017

A P Lebeaut

9

1 reference

26 November 2017

B Yang

10

1 reference

26 November 2017

L E Mellars

11

1 reference

26 November 2017

C Cuffie-Jackson

12

1 reference

26 November 2017

E P Veltri

13

1 reference

26 November 2017

Ezetimibe Study Group

14

1 reference

26 November 2017

1 August 2001

1 reference

26 November 2017

Clinical Therapeutics

1 reference

26 November 2017

23

1 reference

26 November 2017

1209-1230

1 reference

26 November 2017

8

1 reference

Epidemiology of coronary heart disease: the Framingham study.

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Cholesterol biosynthesis and metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Management of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Lipid-altering drugs in development

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Regulation of cholesterol metabolism by dietary plant sterols

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Drug treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980102-8

7 January 2021

10.1016/S0149-2918(01)80102-8

Identifiers

DOI

1 reference

26 November 2017

1 reference